Personalized mRNA Neoantigen Vaccines Demonstrate Durable Melanoma Recurrence Suppression

Byline: Dr. Rachel Aris, Chief Scientific Editor • November 7, 2026 • 6 min read

Long-term survival data from multinational adjuvant clinical trials has confirmed that personalized cancer vaccines—synthesized dynamically based on each patient's unique tumor mutations—provide robust and enduring immunological memory against metastatic recurrence.

Algorithmically Designed Neoantigen Libraries

Each patient's excised tumor undergoes rapid deep-sequencing to identify specific genetic alterations not present in healthy somatic tissue. Advanced HLA-binding prediction algorithms then select the top 34 patient-specific neoantigens possessing the highest probability of provoking a vigorous cytotoxic CD8+ T-cell response.

The synthetic mRNA molecule encoding these targets is formulated into protective lipid nanoparticles and administered alongside standard-of-care anti-PD-1 monoclonal antibodies, preventing the tumor from suppressing the immune onslaught.

← Back to Front Page

Published under the HUTXJ Health & Science Charter